In December 2025, Solventum announced updated consensus recommendations from an international panel on the clinical use of closed incision negative pressure therapy (ciNPT) with its proprietary ...

Expands MedSurg portfolio into the fast-growing synthetic tissue matrices technology space in acute care settings in the U.S. "Announcing and completing our first strategic acquisition is a ...

The S&P healthcare index (XLV) saw moderate gains in 2025, reaching a YTD increase of 12.2% by mid-December, though it fell short of its May highs. The sector is the sixth-highest performing sector ...

The stock market continued to run in place to open the final full trading week of 2025. The S&P 500 and Nasdaq Composite are up in mid-teen percentages and low-20% percentages year to date, ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Solventum (SOLV) been one of those stocks this year? By ...

BTIG’s Top Picks report brings together the firm’s highest-conviction investment ideas drawn from its research platform, with a 12-month investment horizon beginning in the first half of 2026. As the ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.